HomeComparePSCBF vs VIG

PSCBF vs VIG: Dividend Comparison 2026

PSCBF yields 1818.18% · VIG yields 1.64%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PSCBF wins by $4103414683.81M in total portfolio value
10 years
PSCBF
PSCBF
● Live price
1818.18%
Share price
$0.11
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4103414683.84M
Annual income
$3,702,796,788,756,407.00
Full PSCBF calculator →
VIG
Vanguard Dividend Appreciation ETF
● Live price
1.64%
Share price
$210.70
Annual div
$3.45
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32.4K
Annual income
$179.15
Full VIG calculator →

Portfolio growth — PSCBF vs VIG

📍 PSCBF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPSCBFVIG
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PSCBF + VIG cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PSCBF pays
VIG pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PSCBF
Annual income on $10K today (after 15% tax)
$154,545.45/yr
After 10yr DRIP, annual income (after tax)
$3,147,377,270,442,946.00/yr
VIG
Annual income on $10K today (after 15% tax)
$139.33/yr
After 10yr DRIP, annual income (after tax)
$152.28/yr
At 15% tax rate, PSCBF beats the other by $3,147,377,270,442,793.50/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PSCBF + VIG for your $10,000?

PSCBF: 50%VIG: 50%
100% VIG50/50100% PSCBF
Portfolio after 10yr
$2051707341.94M
Annual income
$1,851,398,394,378,293.00/yr
Blended yield
90.24%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PSCBF buys
0
VIG buys
0
No recent congressional trades found for PSCBF or VIG in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPSCBFVIG
Forward yield1818.18%1.64%
Annual dividend / share$2.00$3.45
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$4103414683.84M$32.4K
Annual income after 10y$3,702,796,788,756,407.00$179.15
Total dividends collected$4074760433.31M$1.7K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: PSCBF vs VIG ($10,000, DRIP)

YearPSCBF PortfolioPSCBF Income/yrVIG PortfolioVIG Income/yrGap
1← crossover$192,518$181,818.18$11,304$163.92+$181.2KPSCBF
2$3,477,331$3,271,336.99$12,759$166.33+$3.46MPSCBF
3$58,943,217$55,222,471.89$14,382$168.52+$58.93MPSCBF
4$937,891,469$874,822,227.57$16,192$170.52+$937.88MPSCBF
5$14,012,869,532$13,009,325,660.38$18,210$172.34+$14012.85MPSCBF
6$196,647,994,247$181,654,223,846.76$20,460$173.98+$196647.97MPSCBF
7$2,592,865,386,485$2,382,452,032,641.56$22,968$175.48+$2592865.36MPSCBF
8$32,132,661,421,271$29,358,295,457,731.54$25,763$176.83+$32132661.40MPSCBF
9$374,409,247,740,494$340,027,300,019,734.44$28,878$178.05+$374409247.71MPSCBF
10$4,103,414,683,838,736$3,702,796,788,756,407.00$32,350$179.15+$4103414683.81MPSCBF

PSCBF vs VIG: Complete Analysis 2026

PSCBFStock

Pascal Biosciences Inc., a biotechnology company, engages in the research and development of products for the treatment of cancer, and for the improvement of the immune system. The company's development portfolio includes PAS-403, a mitosis inhibitor that blocks cell division for the treatment of glioblastoma and brain metastases originating from other cancers; and PAS-393, an immune-stimulatory cannabinoid designed to restore the immunogenicity of tumor cells with checkpoint inhibitor therapy for use in cancer treatment. It is also developing a B-cell targeted antibody for acute lymphoblastic leukemia and B cell lymphomas; and cannabinoid therapeutic products for the treatment of COVID-19. The company has an exclusive license agreement with the University of Washington to develop a cannabinoid-based product for the treatment of glioblastoma multiforme and brain metastases; and a collaborative research agreement with SoRSE Technology Corporation to advance PAS-393 into clinical testing. Pascal Biosciences Inc. was incorporated in 2011 and is headquartered in Seattle, Washington.

Full PSCBF Calculator →

VIGETF

Seeks to track the performance of the S&P U.S. Dividend Growers Index.Passively managed, full-replication approach.Fund remains fully invested.Large-cap equity, emphasizing stocks with a record of growing their dividends year over year.Low expenses minimize net tracking error.With respect to 75% of its total assets, the fund may not: (1) purchase more than 10% of the outstanding voting securities of any one issuer or (2) purchase securities of any issuer if, as a result, more than 5% of the fund’s total assets would be invested in that issuer’s securities; except as may be necessary to approximate the composition of its target index. This limitation does not apply to obligations of the U.S. government or its agencies or instrumentalities.

Full VIG Calculator →
📬

Get this PSCBF vs VIG comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PSCBF vs SCHDPSCBF vs JEPIPSCBF vs OPSCBF vs KOPSCBF vs MAINPSCBF vs DGROPSCBF vs NOBLPSCBF vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.